$34.50 0.07 (+0.20%)
11/6/2009 4:01 PM

Eli Lilly & Co. (LLY)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.

Recs

1
Member Avatar bobbyvee (98.15) Submitted: 3/7/2009 11:48:54 AM : Underperform Start Price: $26.95 LLY Score: +32.39

Pharaceuticals will suffer under this administration's plan for universal care

Report this Post 1 Comment
Member Avatar wrparks (60.04) Submitted: 6/2/2009 9:15:16 AM
Recs: 1 Rec This

I disagree. I think their margins may be squeezed due to lower drug prices. But, I expect their volume may increase offsetting this. I'm not highly confident they will outperform, but I don't think your explanation is a very good one.

Featured Broker Partners